The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1750
March 16, 2026
View Complete Issue         Table of Contents 2019 
Obinutuzumab (Gazyva) for Lupus Nephritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Obinutuzumab (Gazyva) for Lupus Nephritis
March 16, 2026 (Issue: 1750)
Obinutuzumab (Gazyva – Genentech), a CD20-directed monoclonal antibody, has been approved by the FDA for treatment of adults with active lupus nephritis who are receiving standard treatment. It was previously approved for treatment of chronic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Obinutuzumab (Gazyva) for Lupus Nephritis
Article code: 1750c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.